New cholesterol drug Praluent faces high cost despite promising efficacy

New cholesterol drug Praluent faces high cost despite promising efficacy The passage discusses the medical and pricing aspects of a new cholesterol drug, mentioning industry executives but no direct ties to high‑level political figures, financial misconduct, or novel controversies. It offers limited investigative value beyond standard pharmaceutical pricing concerns. Key insights: Praluent targets PCSK9 and can lower LDL by up to 60%; Regeneron and Sanofi price it at $40 per day, $14,600 annually; Potential insurer rebates due to competition with Amgen